Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Paul Prather

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmacology & Toxicology, College of Medicine
Address302 Biomedical Research I
325 S. Elm St.
Mail Slot # 611
Little Rock AR 72205
Phone501-686-5512
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    T32GM150536     (PRATHER, PAUL L)Jul 1, 2023 - Jun 30, 2028
    NIH
    Training in Systems Pharmacology and Toxicology (T-SPaT)
    Role: Principal Investigator
    R21DA049585     (BRENTS, LISA KAYE)Aug 1, 2019 - Jul 31, 2021
    NIH
    Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome
    Role: Co-Investigator
    R01DA039143     (PRATHER, PAUL L)May 15, 2016 - Apr 30, 2021
    NIH
    Synthetic Cannabinoid Toxicity: Role of Biotransformation
    Role: Principal Investigator
    T32GM106999     (PRATHER, PAUL L)Jul 1, 2013 - Jun 30, 2023
    NIH
    Systems Pharmacology and Toxicology Training Program
    Role: Principal Investigator
    R21NS058430     (PRATHER, PAUL L)Jul 15, 2008 - Jun 30, 2011
    NIH
    Selective CB2 Cannabinoid Agonists as Candidate Therapeutics for ALS
    Role: Principal Investigator
    CRA     (YACCOBY, SHMUEL)May 17, 2007 - Sep 17, 2008
    Vantia Therapeutics Ltd.
    Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma
    Role: Principal Investigator
    1311     (PRATHER, PAUL L)Feb 1, 2007 - Jan 31, 2009
    ALS Association
    Selective CB2 Cannabinoid Agonists as Candidate Therapeutics for Amyotrophic Lateral Sclerosis (ALS)
    Role: Principal Investigator
    R01DA013660     (PRATHER, PAUL L)Feb 1, 2001 - Jan 31, 2006
    NIH
    CANNABINOID AGONIST REGULATION OF SIGNAL TRANSDUCTION
    Role: Principal Investigator
    R29DA010936     (PRATHER, PAUL L)Jan 15, 1998 - Dec 31, 2003
    NIH
    OPIOID CONTROL MECHANISMS OF SIGNAL TRANSDUCTION
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Janganati V, Salazar P, Parks BJ, Gorman GS, Prather PL, Peterson EC, Alund AW, Moran JH, Crooks PA, Brents LK. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Front Pharmacol. 2023; 14:1123261. PMID: 37229250.
      View in: PubMed
    2. Crosby SV, Ahmed IY, Osborn LR, Wang Z, Schleiff MA, Fantegrossi WE, Nagar S, Prather PL, Boysen G, Miller GP. Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes. Metabolites. 2022 Aug 22; 12(8). PMID: 36005645.
      View in: PubMed
    3. Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicol Sci. 2022 04 26; 187(1):175-185. PMID: 35201352.
      View in: PubMed
    4. Shoeib AM, Benson LN, Mu S, MacMillan-Crow LA, Prather PL. Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. Int J Mol Sci. 2022 Mar 11; 23(6). PMID: 35328467.
      View in: PubMed
    5. Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021 Nov 15; 285:119993. PMID: 34592231.
      View in: PubMed
    6. Fulo HF, Shoeib A, Cabanlong CV, Williams AH, Zhan CG, Prather PL, Dudley GB. Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. J Med Chem. 2021 05 13; 64(9):6381-6396. PMID: 33887913.
      View in: PubMed
    7. Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20). PMID: 33092129.
      View in: PubMed
    8. Yang JF, Williams AH, Penthala NR, Prather PL, Crooks PA, Zhan CG. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. ACS Chem Neurosci. 2020 10 21; 11(20):3455-3463. PMID: 32997485.
      View in: PubMed
    9. Penthala NR, Shoeib A, Dachavaram SS, Cabanlong CV, Yang J, Zhan CG, Prather PL, Crooks PA. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. Bioorg Med Chem Lett. 2020 11 15; 30(22):127501. PMID: 32882418.
      View in: PubMed
    10. Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949. PMID: 32413436.
      View in: PubMed
    11. Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 02; 8(1):e00561. PMID: 32003945.
      View in: PubMed
    12. Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395. PMID: 30739533.
      View in: PubMed
    13. Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269. PMID: 30833484.
      View in: PubMed
    14. Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to ?9-THC. Front Pharmacol. 2018; 9:1084. PMID: 30319418.
      View in: PubMed
    15. Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicol Appl Pharmacol. 2018 08 15; 353:31-42. PMID: 29906493.
      View in: PubMed
    16. Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochem Biophys Res Commun. 2018 04 06; 498(3):597-602. PMID: 29522717.
      View in: PubMed
    17. Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome? Neurosci Lett. 2018 04 23; 673:24-27. PMID: 29490230.
      View in: PubMed
    18. Prather PL. Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. Drug Metab Rev. 2018 02; 50(1):1-2. PMID: 29378464.
      View in: PubMed
    19. Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sci. 2018 Jan 01; 192:151-159. PMID: 29191644.
      View in: PubMed
    20. Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. Br J Pharmacol. 2017 Dec; 174(23):4523-4539. PMID: 28963716.
      View in: PubMed
    21. Yadlapalli JSK, Dogra N, Walbaum AW, Wessinger WD, Prather PL, Crooks PA, Dobretsov M. Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats. Anesth Analg. 2017 09; 125(3):1021-1031. PMID: 28489639.
      View in: PubMed
    22. Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov; 125(Pt B):161-177. PMID: 28838808.
      View in: PubMed
    23. Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017 03; 38(3):257-276. PMID: 28162792.
      View in: PubMed
    24. Franks LN, Ford BM, Prather PL. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Front Pharmacol. 2016; 7:503. PMID: 28066250.
      View in: PubMed
    25. Ford BM, Franks LN, Radominska-Pandya A, Prather PL. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. PLoS One. 2016; 11(12):e0167240. PMID: 27936172.
      View in: PubMed
    26. Yadlapalli JSK, Ford BM, Ketkar A, Wan A, Penthala NR, Eoff RL, Prather PL, Dobretsov M, Crooks PA. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacol Res. 2016 11; 113(Pt A):335-347. PMID: 27637375.
      View in: PubMed
    27. Jalin AM, Rajasekaran M, Prather PL, Kwon JS, Gajulapati V, Choi Y, Kim C, Pahk K, Ju C, Kim WK. Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. PLoS One. 2015; 10(10):e0141600. PMID: 26517721.
      View in: PubMed
    28. Wang J, Zheng J, Kulkarni A, Wang W, Garg S, Prather PL, Hauer-Jensen M. Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. Dig Dis Sci. 2014 Nov; 59(11):2693-703. PMID: 24848354.
      View in: PubMed
    29. Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol. 2014 Aug 15; 737:140-8. PMID: 24858620.
      View in: PubMed
    30. Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun. 2013 Nov 15; 441(2):339-43. PMID: 24148245.
      View in: PubMed
    31. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22. PMID: 24314548.
      View in: PubMed
    32. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ?(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014 Feb 27; 97(1):45-54. PMID: 24084047.
      View in: PubMed
    33. Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014 Feb; 46(1):72-85. PMID: 24063277.
      View in: PubMed
    34. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013 Sep; 346(3):350-61. PMID: 23801678.
      View in: PubMed
    35. Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem. 2013 Jun 13; 56(11):4537-50. PMID: 23631463.
      View in: PubMed
    36. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 Jun 01; 269(2):100-8. PMID: 23537664.
      View in: PubMed
    37. Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem Lett. 2013 Apr 01; 23(7):2019-21. PMID: 23466226.
      View in: PubMed
    38. Choi IY, Ju C, Anthony Jalin AM, Lee DI, Prather PL, Kim WK. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am J Pathol. 2013 Mar; 182(3):928-39. PMID: 23414569.
      View in: PubMed
    39. Ju C, Hwang S, Cho GS, Kondaji G, Song S, Prather PL, Choi Y, Kim WK. Differential anti-ischemic efficacy and therapeutic time window of trans- and cis-hinokiresinols: stereo-specific antioxidant and anti-inflammatory activities. Neuropharmacology. 2013 Apr; 67:465-75. PMID: 23287539.
      View in: PubMed
    40. Madadi, N.R., Penthala, N.R., Brents, L.K., Ford, B.M., Prather, P.L., Crooks, P.A. Design, synthesis, and evaluation (Z)-2-((1-benzyl-1H-indol-3-yl)methylene) quinuclidin-3-one analogues as novel high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorganic and Medicinal Chemistry Letters. 2013; 23(7):2019-2021, PMID 23466226.
    41. Ju, C., Anthony-Jalin, A.M.A., Lee, D.I., Chol, I.Y., Prather, P.L., Kim, W.K. Activation of neuronal CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. American Journal of Pathology. 2013; 182(3):928-939, PMID 23414569.
    42. Fantegrossi, W.E., Franks, L.N., Vasiljevik, T., Prather, P.L. Tolerance and cross-tolerance among high-efficacy synthetic cannabinoids JWH-018 and JWH-073 and low-efficacy phytocannabinoid ?9-THC. Experimental Biology (EB). 2013.
    43. Radominska-Pandya, A., Francisdevaraj, F., Dates, C., Greer, A.K., Bratton, S.M., Pyrek, S., Fahmi, T., Medina-Bolivar, F., Haun, R.S., Prather, P.L. A previously unexplored link between cannabinoid receptors and UDP-glucuronosyltransferases in cancer. International Society for the Study of Xenobiotics (ISSX). 2013.
    44. Madadi, N.R., Prather, P.L., Crooks, P.A. 3,4(Methelenedioxy) substituted stilbenes as selective and high affinity ligands for CB1 and CB2 cannabinoid receptors. Medicinal Chemistry and Pharmacognosy Conference (MALTO). 2013.
    45. Franks, L.N., Ford, B.M., Madadi, N.R., Penthala, N.R., Crooks, P.A., Prather, P.L. Characterization of the intrinsic activity for a novel class of indole quinuclidine analogs (IQDs) exhibiting high nanomolar affinity for CB1 and CB2 cannabinoid receptors. Soc. Neurosci. Abs. 2013.
    46. Dates, C., Francisdevaraj, F., Greer, A.K., Bratton, S.M., Pyrek, S., Fahmi, T., Medina-Bolivar, F., Prather, P.L., Radominska-Pandya, A. Use of natural and synthetic cannabinoids to establish cannabinoid receptors as novel targets for the treatment of breast cancer. International Society for the Study of Xenobiotics (ISSX). 2013.
    47. Brents, L.K, Prather, P.L. The K2/Spice phenomenon: The emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews. 2013.
    48. Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem. 2012 Dec; 12(10):1211-20. PMID: 22583404.
      View in: PubMed
    49. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012 Nov; 40(11):2174-84. PMID: 22904561.
      View in: PubMed
    50. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15. PMID: 22771770.
      View in: PubMed
    51. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther. 2012 Jul; 11(7):1421-31. PMID: 22553354.
      View in: PubMed
    52. Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012 Apr 16; 25(4):825-7. PMID: 22404317.
      View in: PubMed
    53. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012 Apr 01; 83(7):952-61. PMID: 22266354.
      View in: PubMed
    54. Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the ?-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of ?2-adrenergic receptors with N-terminal polymorphisms. Cell Biol Int. 2012; 36(12):1171-83. PMID: 22938397.
      View in: PubMed
    55. Koryakina, Y., Jones, S.M., Cornett, L.E., Seely, K.A., Brents, L.K., Prather, P.L., Kofman, A., Kurten, R.C. The effects of the ß-agonist isoproterenol on the down-regulation, functional responsiveness, and trafficking of the ß2-adrenergic receptors with amino-terminal polymorphisms. Cell Biology International. 2012; 36(12):1171-1183, PMID 22938397.
    56. Liu, X., Jutooru, I., Lei, P., Kim, K.H., Lee, S.O., Brents, L.K., Prather, P.L., Safe, S. H. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microrRNA-27a:ZBTB10 in breast cancer. Molecular Cancer Therapeutics. 2012; 11(7):1421-1431, PMID 22553354.
    57. Penthala, N.R., Brents, L.K., Prather, P.L., Crooks, P.A. Design and synthesis of active N-benzylindol-3-yl quinuclidins as novel cannabinoid ligands. Medicinal Chemistry and Pharmacognosy Conference (MALTO). 2012.
    58. Brents, L.K., Medina-Bolivar, L.F., Seely, K.A., Nair, V., Bratton, S.M., Nopo-Olabazal, L., Patel, R.Y., Liu, H., Doerksen, R.J., Prather, P.L., Radominska-Pandya, A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronide profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012; 42(2):139-156, PMID 21970716.
    59. Medina-Bolivar, F., Radominska-Pandya, A., Nopo-Olazabal, L., Atwill, R., Condori, J., Nopo Olazabal, C., Carrier, D., Srivatsan, M., Prather, P.L, Doerksen, R. Bioproduction and biological activity of the natural prenylated resveratrol analogs arachidin-1 and arachidin-3. International Conference on Resveratrol and Health. 2012.
    60. Penthala, N.R., Brents, L.K., Prather, P.L., Crooks, P.A. Design and synthesis of active indole quinuclidinones as novel cannabinoid ligands. American Association of Pharmaceutical Scientists (AACP). 2012.
    61. Czerwinska,, A., Bratton, S.M., Dates, C., Francisdevaraj, F., Rajasekaran,, M., Prather, P.L., Radominska-Pandya, A. Gambogic acid and its analogues are novel substrates for human UDP-glucuonosyltransferase and bind cannabinoid receptors CB1 and CB2. Annual Conference American Council for Medicinally Active Plants (ACMAP). 2012.
    62. Vasiljevik, T., Brents, L.K, Prather, P.L., Fantegrossi, W.E., Prisinzano, T.E. Further Elucidation of the SAR of K2/Spice Aminoalkylindoles. International Narcotics Research Conference (INRC). 2012.
    63. Prather, P.L., Radominska-Pandya, A., Medina-Bolivar, F., Doerksen, R.J. Natural prenylated and synthetic resveratrol analogs as novel ligands for cannabinoid receptors. Annual Conference American Council for Medicinally Active Plants (ACMAP). 2012.
    64. Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012 Feb; 42(2):139-56. PMID: 21970716.
      View in: PubMed
    65. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917. PMID: 21755008.
      View in: PubMed
    66. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem. 2011 Jun 01; 83(11):4228-36. PMID: 21506519.
      View in: PubMed
    67. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011 Feb; 11(1):36-51. PMID: 21441120.
      View in: PubMed
    68. Chimalakonda, K.C., Brents, L.K., Moran, C.L., Prather, P.L., James, L.P., Radominska-Pandya, A, Jeffery H. Moran. Simultaneous Urinary Identification and Quantification and In Vitro Characterization of Omega and Omega-1 Metabolites of the abused synthetic cannabinoids JWH-018 and JWH-073. International Society for the Study of Xenobiotics (ISSX). 2011.
    69. Moran, C.L., Le, V.H., Chimalakonda, K.C., Smedley, A.L., Lackey, F.D., Owen, S. N., Kennedy, P.D., Endres, G.W., Ciske, F.L., Kramer, J.B., Kornilov, A.M., Bratton, L.D., Dobrowolski, P.J., Wessinger, W.D., Fantegrossi, W.E., Prather, P.L., James, L.P., Radominska-Pandya, A., Moran, J.H. Quantitative measuerment of JWH-018 and JWH-073 metabolites excerted in human urine. Analytical Chemistry. 2011; 83(11):4228-4236, PMID 21506519.
    70. Brents, L.K., Gallus-Zawada, A., Radominska-Pandya, A., Fantegrossi, W.E., Moran, J.H., Prather, P.L. A mono-hydroxylated metabolite of the K2 synthetic cannabinoid JWH-073 displays high affinity neutral antagonism at CB1 receptors. International Cannabinoid Research Society (ICRS). 2011.
    71. Moran, C.L., Lackey, F.D., Patton, A.L., Moran, J.H., James, L.P., Fantegrossi, W.E., Prather, P.L., Radominska-Pandya, A., McCain, K.R. Developing a Model Statewide Forensic Surveillance and Toxicology Testing Program for Designer Drugs,. Society of Crime Laboratory Directors (ASCLD). 2011.
    72. Moran, J.H., Le, V.H., Blevins, J.M., Moran, C.L., Bratton, S.M., Chib, S., Gallus-Zawada, A., Prather, P.L., Fantegrossi, W.E., Wessinger, W.E, Radominska-Pandya, A., James, L.P. Combining innovation with translation science to develop a model statewide forensic testing and biomonitoring program in Arkansas. National Meeting for Public Health Laboratories (NMPHL). 2011.
    73. Brents, L.K., Rajesekaran, M., Franks, L., Moran, J.H., Prather, P.L. The omega and omega-1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s). Experimental Biology (EB). 2011.
    74. Prather, P.L., Cortez, L.K., Nopo-Olazabal, L., Nair, V, Medina-Bolivar, F., Radominska-Pandya, A. Natural resveratrol analogues arachidin-1, arachidin-4 and hydroxylated metabolites binding human and mice cannabinoid receptors CB1 and CB2,. 2010.
    75. Radominska-Pandya, A, Yiewl, K.H., Bratton, S.M., Gallus-Zawadal, A., Fantegrossi, W.E., James, L.P., Moran, J.C., Moran, J.H., Prather, P.L. Biotransformation of abused synthetic cannabinoids in K2/Spice by human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs). International Society for the Study of Xenobiotics (ISSX). 2010.
    76. Cortez, L.K., Reichard, E.E., Moran, J.H., Fantegrossi, W.E., Prather, P.L. Hydroxylated metabolites of the synthetic cannabinoid JWH-018 retain in vitro and in vivo affinity and activity at CB1 cannabinoid receptors. Experimental Biology (EB). 2010.
    77. Radominska-Pandya, A., Nair, V., Bratton, S.M., Gallus-Zawada, A., Prather, P.L., Medina-Bolivar, F. Human UDP-glucuronosyltransferases (UGTs) are involved in the metabolism of transArachidins and Piceatannol. 2010.
    78. Prather PL, Seely KA, Levi MS. Notice of retraction. J Pharmacol Exp Ther. 2009 Dec; 331(3):1147. PMID: 19940110.
      View in: PubMed
    79. Seely KA, Levi MS, Prather PL. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. J Pharmacol Exp Ther. 2009 Jul; 330(1):31-9. PMID: 19359525.
      View in: PubMed
    80. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009 Jul; 37(7):1496-504. PMID: 19339377.
      View in: PubMed
    81. Rajasekaran, M., Prather, P.L. Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity. 2009.
    82. Prather, P.L. Cannabinoids and the Brain. CB2 Cannabinoid receptors: Molecular, signaling and trafficking properties. 2008; 75-90.
    83. Hayes, C.J., Seely, K.A., Holthoff, J.H., Mayeux, P.R., Prather, P.L. Do Cannabinoid receptors in the kidney play a role in sepsis-induced kidney injury?. Arkansas Association of Public Universities Annual Conference (AAPUAC). 2008.
    84. Seely, K.A., Prather, P.L. The polyphenols curcumin, ASC-J9 and resveratrol act as selective CB1 cannabinoid receptor antagonists/inverse agonists. Soc. Neurosci. Abs. 2008; 34, Program No. 563.8.
    85. Seely, K.A. The polyphenols curcumin, ASC-J9 and resveratrol act as selective CB1 cannabinoid receptor antagonists/inverse agonists. Soc. Neurosci. Abs. 2008.
    86. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007 Apr; 101(1):87-98. PMID: 17241118.
      View in: PubMed
    87. Shoemaker, J.L., Ruckle, M.B., Mayeux, P.R., Prather, P.L. Agonist-directed trafficking of CB2 receptors. CB2 Cannabinoid Receptors: New Vistas. 2007; Abstract Program p. 10.
    88. Romanovsky, D., Chowdhury, P., Cruz, N.F., Dienel, G.A., Hennings, L., Prather, P.L., Dobretsov, M. STZ-normoglycemic rats as a prospective animal model for studies of pathogenesis of pre-diabetic neuropathy. American Diabetes Association Abs. 2006.
    89. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther. 2005 Nov; 315(2):828-38. PMID: 16081674.
      View in: PubMed
    90. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther. 2005 Aug; 314(2):868-75. PMID: 15901805.
      View in: PubMed
    91. Tiwari MM, Prather PL, Mayeux PR. Mechanism of bradykinin-induced Ca2+ mobilization in murine proximal tubule epithelial cells. J Pharmacol Exp Ther. 2005 May; 313(2):798-805. PMID: 15665141.
      View in: PubMed
    92. Shoemaker, J.L., Joseph, B.K., Ruckle, M.B. Noladin ether acts as a full agonist at human CB2 cannabinoid receptors stably expressed in CHO cells. FASEB J. 2005; 19(4): Program No. 318.10.
    93. Shoemaker, J.L., Ruckle, M.B., Mayeux, P.R., Prather, P.L. Agonist-directed trafficking by endocannabinoids acting at CB2 receptors. Soc. Neurosci. Abs. 2005; 31: Program No. 563.14.
    94. Tiwari, M.M., Prather, P.L., Stimers, J.R., Mayeux, P.R. Bradykinin B2 signaling in the TKPTS muring proximal tubular epithelial cell line. FASEB J.,. 2005; 19(4): Program No. 90.4.
    95. Prather PL. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors. Sci STKE. 2004 Jan 05; 2004(215):pe1. PMID: 14722344.
      View in: PubMed
    96. Liu JG, Prather PL. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. J Pharmacol Exp Ther. 2002 Sep; 302(3):1070-9. PMID: 12183665.
      View in: PubMed
    97. Martin NA, Ruckle MB, VanHoof SL, Prather PL. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. J Pharmacol Exp Ther. 2002 May; 301(2):661-71. PMID: 11961071.
      View in: PubMed
    98. Liu, J.G., Prather, P.L. Chronic agonist exposure converts antagonists into inverse agonists at delta-opioid receptors. 2002.
    99. Liu, J.G., Prather, P.L. Chronic agonist treatment converts antagonists into inverse agonists at ?-opioid receptors. J. Pharmacol. Exp. Ther. 2002; 303:1070-1079, PMID 12183666.
    100. Martin, N.A., Ruckle, M.B., Prather, P.L. Agonist, antagonist and inverse agonist characteristics of TIPP, a selective ?-opioid receptor ligand. J. Pharmacol. Exp. Ther. 2002; 301:661-671, PMID 11961071.
    101. Liu, J.G. Relationship to delta-opioid receptor down-regulation reveals a potential dissociation of spontaneous and antagonist-precipitated cAMP overshoot following chronic agonist exposure. Soc. Neurosci. Abs. 2002; 28: Program No. 241.7.
    102. Martin, N.A., Prather, P.L. Agonist activity of delta antagonists TIPP and TIPP[psi] in cellular models expressing endogenous or transfected delta opioid receptors. Soc. Neurosci. Abs. 2001; 27: Program No. 40.11.
    103. Martin, N.A., Prather, P.L. Interaction of co-expressed ?- and ?-opioid receptors in GH3 cells. Mol. Pharmacol. 2001; 59:774-783, PMID 11259622.
    104. Liu, J.G., Ruckle, M.B., Prather, P.L. Constitutively active ?-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. J. Biol. Chem. 2001; 276(41):37779-37786, PMID 11500514.
    105. Liu, J.G., Prather, P.L. Chronic exposure to ?-opioid agonists produces constitutive activation of ?-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol. Pharmacol. 2001; 60:53-62, PMID 11408600.
    106. Liu, J.G., Prather, P.L. Chronic exposure to selective agonists produces constitutive activation of ?-opioid receptors in direct proportion to agonist efficacy. Soc. Neurosci. Abs. 2001; 27: Program No. 40.13.
    107. Prather, P.L., Martin, N.A., Breivogel, C.S., Childers, S.R. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein ?-subunits with different potencies. Mol. Pharmacol. 2000; 57:1000-1010, PMID 10779385.
    108. Childers, S.R., Vogt, L., Prather. P.L, Rasenick, M. Localization of receptor-activated G? subunits in brain sections by [32P]azido-anilido-GTP autoradiography. Soc. Neurosci. Abs. 2000; 26:637.
    109. Prather, P.L., Zhang, H., Law, P.Y., Song, L., Hales, T.G. ?-Opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca2+ channels in transfected rat pituitary cells. J. Pharmacol. Exp. Ther. 2000; 295(2):552-562, PMID 11046088.
    110. Martin, N.A., Prather, P.L. Interaction of co-expressed mu and delta opioid receptors in GH3 cells. Soc. Neurosci. Abs. 2000; 26:1156.
    111. Martin, N.A., Prather, P.L. Differential stimulation of G proteins by the cannabinoid agonist WIN 55212-2. FASEB J. 2000; 14(8):A1448.
    112. Prather, P.L., Zhang, H., Law, P.Y., Song, L., Hales, T.G. ?-Opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca2+ channels in transfected rat pituitary cells. Soc. Neurosci. Abs. 1999; 25:1221.
    113. McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain. 1998 Nov; 78(2):79-98. PMID: 9839818.
      View in: PubMed
    114. Prather, P.L., Adams, J.L. Differential coupling of cloned ?- and ?-opioid receptors to G-protein ?-subunits and effectors in transfected rat pituitary cells. Soc. Neurosci. Abs. 1998; 24:851.
    115. Adams, J.L. Use of a cloned epitope tagged ?-opioid receptor as a means to elucidate receptor/G protein interactions. Soc. Neurosci. Abs. 1997; 23:676.
    116. McComack, K., Brune, K., Budd, K., Prather, P.L. Experimental indicies used to classify opioids as partial or full receptor agonists may have limited clinical utility. World Congress on Pain Abstracts. 1996; p. 464.
    117. Prather, P.L., Brune, K., Budd, K., McCormack, K. How far does functional promiscuity amongst receptor subtypes and G proteins explain diversity in clinical effects and interactions?. 8th World Congress on Pain Abstracts. 1996; 460.
    118. Piros, E.T., Prather, P.L., Law, P.Y., Evans, C.J., Hales, T.G. Voltage-dependent inhibition of L-type Ca2+ channels by cloned ?- and ?-opioid receptors. Mol. Pharmacol. 1996; 50:947-956, PMID 8863841.
    119. Forster, M.J., Prather, P.L., Patel, S.R., H. Lal. The benzodiazepine inverse agonist, RO 15-3505, reverses recent memory deficits in aged mice. Pharmacol. Biochem. Behav. 1995; 51(2-3):557-560, PMID 7667387.
    120. Claude, P., Erickson, L.J., Prather, P.L., Loh, H.H., Law, P.Y. Single amino acid mutation in transmembrane region confers agonist activity to antagonists. Soc. Neurosci. Abs. 1995; 21:1605.
    121. Prather, P.L., McGinn, T.M., Claude, P.A., Liu-Chen, L.Y., Loh, H.H., Law, P.Y. Properties of a kappa opioid receptor expressed in CHO cells: Interaction with multiple G-proteins is not specific for any G??subunit and is similar to that of other opioid receptors. Mol. Brain Research. 1995; 64:2534-2543, PMID 7609621.
    122. Chakrabarti, S., Prather, P.L., Yu, L., Law, P.Y., Loh, H.H. Expression of the ?-opioid receptor in CHO cells: Ability of ?-opioid ligands to promote [32P]-?-azidoanilido GTP labeling of multiple G protein ?-subunits. J. Neurochem. 1995; 64:2534-2543, PMID 7760033.
    123. Piros, E.T., Prather, P.L., Law, P.Y., Evans, C.J., Hales, T.G. Inhibition of voltage-activated calcium channels and adenylyl cyclase by transfected ?- and ?-opioid receptors in GH3 cells. Soc. Neurosci. Abs.,. 1995; 21:1997.
    124. Piros, E.T., Prather, P.L., Loh, H.H., Law, P.Y., Evans, C.J., Hales, T.G. Ca2+ channel and adenylyl cyclase modulation by cloned ?-opioid receptors in GH3 cells. Pharmacol. 1995; 47:1041-1049, PMID 7746271.
    125. Prather, P.L., Loh, H.H., Law, P.Y. Interaction of ?-opioid receptors with multiple G-proteins: A non-relationship between agonist potency to inhibit adenylyl cyclase and activation of G-proteins. Mol. Pharmacol. 1994; 45:997-1003, PMID 8190115.
    126. Prather PL. Ability of ?-opioid receptors to interact with multiple G-proteins is independent of receptor density. J. Biol. Chem. 1994; 269(33):21293-21302, PMID 8063754.
    127. Prather, P.L., McGinn, T.M., Claude, P.A., Liu-Chen, L.Y., Loh, H.H., Law, P.Y. Properties of a kappa opioid receptor expressed in CHO cells: Ability to activate multiple G-proteins is similar to other opioid receptors. Soc. Neurosci. Abs. 1994; 20:1732.
    128. Chakrabarti, S., Prather, P.L., Yu, L., Law, P.Y., Loh, H.H. Expression of the ?-opioid receptor in CHO cells: Ability of ?-opioid ligands to promote [32P]-?-azidoanilido GTP labeling of multiple G protein ?-subunits. International Narcotics Research Conference Abs. 1994.
    129. Prather, P.L., McGinn, T.M., Erickson, L.J., Evans, C.J., Loh, H.H., Law, P.Y. Ability of ?-opioid receptors to interact with multiple G-proteins is independent of receptor density. International Narcotics Research Conference Abs. 1994.
    130. Bhadra, S., Prather, P.L., Elkhayat, I., Harris, C.M., Lal, H. Anxiogenic effects of disulfiram evaluated in an animal model. J. Stud. Alcohol. 1993; 54(1):5-10, PMID 8394957.
    131. Rezazadeh, S.M., Prather, P.L., Lal, H. Sensitization to 5HT1c receptor agonists in rats observed following withdrawal from chronic ethanol. Alcohol. 1993; 10:281-283, PMID 8397879.
    132. Prather, P.L., Tsai, A.W., Law, P.Y. Mu and delta receptor desensitization in undifferentiated human neuroblastoma SH-SY-5Y cells. FASEB J. 1993; 7(4):A704.
    133. Prather, P.L., Loh, H.H., Law, P.Y. Coupling of delta opioid receptors to four distinct G-proteins in neuroblastoma x glioma NG108-15 hybrid cells. Pharmacologist. 1993; 35(3):140.
    134. Lal, H., Prather, P.L., Luedtke, R.R., Forster, M.J. Reversal of age-related cognition deficits in autoimmune mice by 647U, a potential new nootropic. Soc. Neurosci. Abs. 1992; 18:522.
    135. Rezazadeh, S.M., Prather, P.L., Lal, H. Sensitization to 5-HT1C receptor agonists in ethanol (ETOH) withdrawal rats. International Narcotics Research Conference Abs. 1992.
    136. Lal, H., Prather, P.L., Benjamin, D., Rezazadeh, S.M. Concurrent attenuation of ethanol-withdrawal symptoms and down-regulation of 5HT2 and 5HT1c receptors by mianserin. Alcoholism: Clin. and Exp. Res. 1991; 15(2):332.
    137. Lal, H., Rezazadeh, S. M., Prather, P.L. Clozapine reverses anxiogenic behaviors observed during ethanol withdrawal. Pharmacologist. 1991; 33:165.
    138. Rezazadeh, S.M., Prather, P.L., Lal, H. Evaluation of anxiogenic behaviors during ethanol withdrawal in three strains of rats utilizing the elevated plus-maze. Soc. Neurosci. Abs. 1991; 17:1419.
    139. Prather, P.L., Rezazadeh, S.M., Lal, H. Ondansetron-induced reversal of anxiogenic behaviors upon withdrawal from ethanol: Assessment by behavioral alterations in the elevated plus-maze. Soc. Neurosci. Abs. 1991; 17:1419.
    140. Lal, H., Prather, P.L., Rezazadeh, S.M., Pickering, C.L., Hooper, Emmett-Oglesby, M.W. Ondansetron (OND) selectively prevents 5-hydroxytryptamine (5HT) related behaviors indicative of anxiety during benzodiazepine withdrawal. Proc. N.Y. Acad. Sci. Abs. 1991.
    141. Prather, P.L., Lal, H. Anxiogenic stimuli produced by cocaine are potentiated during protracted withdrawal from concurrently administered cocaine and ethanol in rats. Soc. Neurosci. Abs. 1990; 16:580.
    142. Prather, P.L., Rezazadeh, S.M., Lal, H. Mianserin prevents behaviors indicative of anxiety during ethanol withdrawal in the rat. Proc. Am. Coll. Neuropsychopharmacol. 1990.
    143. Lal, H., Prather, P.L. Anxiety as a symptom of protracted ethanol-withdrawal (EW): Characterization in an animal model. Alcoholism: Clin. and Exp. Res. 1990; 14(2):307.
    144. Rezazadeh, S.M., Prather, P.L., Lal, H. Anxiogenic behavior during ethanol withdrawal: Reversal by buspirone as evaluated in the elevated plus maze. Soc. Neurosci. Abs. 1990; 16:755.
    145. Lal, H., Prather, P.L. Protracted ethanol withdrawal in rats: Tolerance to the anxiolytic effects of diazepam and pentobarbital. FASEB J. 1990; 4:A678.
    146. Ahanotu, E.N., Lal, H., Prather, P.L., Foster, M.J. Caloric restriction prevents age-associated impairments in learning of a maze strategy by autoimmune mice. Soc. Neurosci. Abs. 1990; 16:440.
    147. Prather, P.L., Iturrian, W.B. Sensory kindling in gerbils is a protein dependent process requiring previous seizure. Soc. Neurosci. Abs. 1988; 14:7.
    148. Prather, P.L., Iturrian, W.B. Habituation and postictal inhibition control long term (days) brain excitability in hamsters and gerbils. Faseb J. 1988; 2(5):A1068.
    149. Prather, P.L., Iturrian, W.B. Previous experience in the seizure prone Mongolian gerbil determines kindling or habituation to subsequent seizure tests. Proc. Soc. Exp. Biol. Med. 1988; 187:379.
    150. Prather, P.L., Iturrian, W.B. An integrative model of long term brain excitability for seizure regulation in the epileptic gerbil involving feedback, feedforward, and adaptive mechanisms. Pharmacologist. 1987; 30(3):A119.
    151. Prather, P.L., Iturrian, W.B. Endogenous anticonvulsant systems that control seizures in gerbils and hamsters. Soc. Neurosci. Abs. 1987; 13:52.
    152. Prather, P.L., Iturrian, W.B. Audiodesensitization induces an endogenous anticonvulsant system that prevents spontaneous seizures in gerbils and hamsters. Soc. Neurosci. Abs. 1985; 1317.
    153. Prather, P.L., Iturrian, W.B. Endogenous anticonvulsant system in recurrent seizures: Indomethacin has minor postictal effects. Georgia J. of Sci. 1985; 43:27-28.
    154. Prather, P.L. Endogenous Control of Long Term Seizure Susceptibility: Behavioral and Pharmacological Influence. Thesis.
    155. Hemingway, R.B., Prather, P.L., Reigle, T.G. Prevention of learned helplessness and associated decreases in brain noradrenergic activity by intrahippocampal injections of naloxone. Soc. Neurosci. Abs.,. 12:913.
    156. Seely, K.A., Prather, P.L. In Methods for Discovery and Characterization of G-Protien-coupled Receptors. Characterizing the pharmacology of G protien-coupled receptors in transfected cell lines. 60.
    Prather's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (270) concept(s)
    _
    Co-Authors Expand Description
    See all (19) people
    _
    Similar People Expand Description
    See all (38) people
    _
    Same Department Expand Description
    Search Department